0.0000 (0.0000%)
  • Bid / Lots
    3.0500/ 5
  • Ask / Lots
    3.8000/ 3
  • Open / Previous Close
    0.0000 / 3.9200
  • Day Range
  • 52 Week Range
    Low 2.9800
    High 13.8500
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.99
09:32 ET4023.96
09:41 ET3003.99
09:56 ET4973.99
10:01 ET1273.9649
10:03 ET8963.95
10:15 ET10004.0099
10:17 ET5003.985
10:19 ET1003.96
10:32 ET24453.96
10:35 ET11003.965
10:37 ET8003.95
10:42 ET3113.9501
10:51 ET16043.98
11:13 ET5393.9612
11:26 ET2253.9649
11:27 ET5003.964
11:33 ET4003.99
11:36 ET1003.99
12:02 ET14003.98
12:03 ET6003.97
12:09 ET3293.95
12:27 ET7063.98
12:32 ET10603.96
12:43 ET1003.98
12:59 ET1004
01:12 ET1003.9701
01:14 ET2003.97
01:15 ET19983.9832
01:19 ET1003.97
01:24 ET2003.98
01:30 ET9083.965
01:32 ET8363.9688
01:37 ET1003.95
01:42 ET3003.96
01:44 ET6363.97
01:53 ET4583.99
01:57 ET1003.975
02:00 ET1003.97
02:15 ET11283.98
02:18 ET4003.98
02:24 ET21003.99
02:29 ET3003.97
02:38 ET3003.96
02:40 ET1003.96
02:44 ET1003.95
02:51 ET1003.95
02:58 ET3003.95
03:05 ET2003.9401
03:09 ET1003.955
03:12 ET1003.94
03:14 ET9623.95
03:16 ET1003.945
03:18 ET1003.93
03:20 ET3003.95
03:25 ET1003.94
03:32 ET1003.94
03:34 ET3003.95
03:39 ET1003.932
03:41 ET2003.93
03:43 ET3003.935
03:54 ET5543.93
03:56 ET4003.93
03:57 ET5003.93
03:59 ET9463.92
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRPTX
Repare Therapeutics Inc
United StatesRCEL
AVITA Medical Inc
United StatesMGX
Metagenomi Inc
United StatesDTIL
Precision BioSciences Inc
United StatesIPHA
Innate Pharma SA
United StatesCRBU
Caribou Biosciences Inc
As of 2024-06-14

Company Information

Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.

Contact Information

7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1


Independent Chairman of the Board
Thomas Civik
President, Chief Executive Officer, Director
Lloyd Segal
Chief Financial Officer, Executive Vice President
Steve Forte
Executive Vice President, Chief Scientific Officer
Michael Zinda
Executive Vice President, Chief Medical Officer
Maria Koehler

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.